Drug combinations used for the treatment of non-small-cell lung cancer (NSCLC) and melanoma aren’t as effective as they could be. That could change with a new algorithm developed by a cross-disciplinary Vanderbilt University team for calculating drug synergy.
News: Lung Cancer
Lucy Spalluto, MD, and Jennifer Lewis, MD, MS, are co-leading the Veterans Affairs-Partnership to increase Access to Lung Screening (VA-PALS) National Program Evaluation, which aims to implement lung screening programs and improve access to early detection of lung cancer for at-risk veterans.
A recent study shows that a cell receptor, SSTR2, is a candidate biomarker for poor prognosis and a potential therapeutic target for small cell lung cancer.
Patients who received atezolizumab in addition to standard chemotherapy lived two months longer than those treated with chemotherapy alone, according to a recent study published in the New England Journal of Medicine.
A potential cancer drug aimed at enhancing the effectiveness of ionizing radiation in lung cancer patients is a step closer to development with funding support from the Small Business Innovation Research (SBIR) program.
A recent study suggests that a transporter protein called xCT may be potential therapeutic target in lung cancer.
A group of young lung cancer patients and their family members recently toured research laboratories to learn how investigators are working to find better therapies and possibly a cure for the disease.
The grant from the National Cancer Institute, establishes a research center for advancing the understanding and treatment of small cell lung cancer. Vito Quaranta, M.D., will direct the new center.
The risk of lung cancer drops substantially within five years of quitting, according to a new analysis of the landmark Framingham Heart Study by researchers at Vanderbilt University Medical Center.
A new technology may allow doctors to better distinguish benign from malignant lung nodules in CT-based lung cancer screening.